Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 14/20 | 0.49 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480699 | 0.92 | FBP1 (0.46) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL5479986 | 0.89 | FBP1 (0.46) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL21188213 | 0.87 | FBP1 (0.48) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL21753046 | 0.86 | SRC (0.40) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL21016866 | 0.85 | PPARA (0.47) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL20702486 | 0.84 | SRC (0.46) | FBP1PPARASRCPPARGPPARD | |
| SCHEMBL814816 | 0.84 | FBP1 (0.45) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL5491062 | 0.84 | FBP1 (0.49) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL5100820 | 0.84 | FBP1 (0.49) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL14414921 | 0.84 | FBP1 (0.49) | FBP1PPARAABCB11CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393909-A1 | HYDANTOIN COMPOUND AND MEDICAL USE THEREOF | Harbin Medisan Pharmaceutical Co., LTD. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-3696166-B1 | AMORPHOUS PYRROLIDINE DERIVATIVE AS PPAR AGONIST AND PREPARATION METHOD THEREOF | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023138302-A1 | HYDANTOIN COMPOUND AND MEDICAL USE THEREOF | 哈尔滨三联药业股份有限公司 | 2023-07-27 | — | — | WO | disclosed |
| EP-3486231-B1 | PYRROLIDINE DERIVATIVE SERVING AS PPAR AGONIST | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019186410-A1 | SOLID FORMS OF ELAFIBRANOR AND PROCESSES THEREOF | LUPIN LIMITED (IN) | 2019-10-03 | — | — | WO | disclosed |
| US-20190225597-A1 | PYRROLIDINE DERIVATIVES AS PPAR AGONISTS | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-07-25 | — | — | US | disclosed |
| EP-3486231-A1 | PYRROLIDINE DERIVATIVE SERVING AS PPAR AGONIST | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-05-22 | — | — | EP | disclosed |
| US-8461212-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2013-06-11 | — | — | US | disclosed |
| US-8461212-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2012-05-24 | — | — | US | disclosed |
| EP-1525177-B1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2007-06-27 | — | — | EP | disclosed |
| EP-1519908-B1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2007-06-13 | — | — | EP | disclosed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | disclosed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | disclosed |
| EP-1731513-A1 | PHENOXYACETIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-13 | — | — | EP | disclosed |
| EP-1685113-A1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050222424-A1 | Phenyloxyalkanonic acid derivatives as hppar activators | SMITHKLINE BEECHAM CORPORATION | 2005-10-06 | — | — | US | disclosed |
| WO-2005049578-A1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-02 | — | — | WO | disclosed |
| EP-1513796-A2 | PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004000785-A2 | PHENYLOXYALKANONIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | PSEN1, BACE1, PSEN2 | FBP1 314/4885PPARA 69/4885ABCB11 4084/4885 |
| US-20050222424-A1 | Phenyloxyalkanonic acid derivatives as hppar activators | CEL, HPN, LIPA | FBP1 393/4885PPARA 54/4885ABCB11 18/4885 |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | BRCA1, COL1A1, APOL1 | FBP1 1127/4885PPARA 112/4885ABCB11 3079/4885 |
| US-20190225597-A1 | PYRROLIDINE DERIVATIVES AS PPAR AGONISTS | PPARD, PPARA, PPARG | FBP1 1668/4885PPARA 2/4885ABCB11 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.